Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

An Interview With Franco Negron
Simtra’s capability to support high-volume injectables and lower-volume modalities provides balanced expertise across the sterile injectables landscape. read more
Horizon Lines: A Quarterly Review of NDAs – January-March, 2026
The NDAs approved during the first quarter of 2026 have been divided into the dosage forms Injection, Tablets, Capsules, Oral solution, Gas, and other. read more
The Next Test for AI in Pharmacovigilance Is Trust, Not Accuracy
An AI model can be right and still not be trusted. That’s what Bristol Myers Squibb (BMS) found six months into rolling out AI-powered adverse event processing: while F1 performance scores were tracking upward, the audit trail found reviewers still reopening cases the system had already cleared. read more
Patient-Centric Drug Delivery
Across modalities and markets, patient-centric drug delivery is converging on three themes: self-administration at home, integration of drug delivery device platforms earlier in clinical trials, and alignment of formulations with device and human factors requirements. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Minaris, Asimov Partner on AAV Gene Therapy Manufacturing
Monday, September 28, 2026
Minaris and Asimov have formed a partnership to incorporate Minaris’ OXGENE technology into Asimov’s AAV Edge producer cell lines for manufacturing ... read more
Biodextris Names Clement Fourny CEO
Monday, September 28, 2026
Biodextris has appointed Clement Fourny as chief executive officer, the Laval, Quebec-based biologics contract development and manufacturing ... read more
Lonza Capsugel Adds Capsule Nitrite Testing for Nitrosamine Assessments
Monday, September 28, 2026
Lonza Capsugel has introduced a service to help drugmakers measure nitrite in empty gelatin capsules and assess whether it could contribute to ... read more
CARBOGEN AMCIS Reports FDA Inspection Without Form 483
Monday, September 28, 2026
CARBOGEN AMCIS said its Vionnaz, Switzerland, facility completed its first FDA pre-approval inspection without receiving a Form 483. read more
4basebio, TriLink to Supply Materials for Phase 1 Cell Therapy Trial
Monday, September 28, 2026
4basebio and TriLink BioTechnologies will provide DNA starting material and mRNA manufacturing services for an unnamed multinational pharmaceutical ... read more